Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Thomas K SearsDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0003-3834-2439
Wenxia WangDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0003-4681-8783
Michael DrummDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Dusten UnruhBeckman Coulter, Chaska, MN 55318, USA.
Matthew McCordDepartment of Pathology, Division of Neuropathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0001-7673-4463
Craig HorbinskiDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0001-8340-9992
Funding
Targeting IDH mutations to improve seizure control in glioma patientsR01NS118039 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL, SWANSON, GEOFFREY T · 2020 to 2024
$2.2M
Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and MalignancyR01NS102669 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL · 2017 to 2021
$1.7M
Interaction between Tissue Factor, Junctional Adhesion Molecule-A, and Integrin B1 to drive self-renewal in glioblastomaR01NS117104 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL, LATHIA, JUSTIN D. · 2020 to 2024
$1.5M
Mechanisms and therapeutic implications of temozolomide resistance in glioblastomaF32CA264883 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCCORD, MATTHEW · 2022 to 2023
$148k
American Cancer Society PF-23-1156935-01-ETNCI NIH HHS F32 CA264883NCI NIH HHS F32CA264883NINDS NIH HHS R01 NS102669NINDS NIH HHS R01 NS117104NINDS NIH HHS R01NS117104NINDS NIH HHS R01 NS118039NINDS NIH HHS R01NS118039
6 · The paper itself
Abstract
BACKGROUND/
objectivesThe gene
methodsWe treated IDH
resultsTisVed was more active against cultured IDH
conclusionsTisVed targets high-TF-expressing IDH
Indexed as
antibody–drug conjugateblood coagulation and hemostasisF3/tissue factorglioblastomaIDH mutant glioma
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.